Inventiva Sa

Inventiva Sa EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Inventiva Sa (IVA) as of Oct 17, 2026 is -154.60 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -110.63 M USD — a change of 39.74% (lower).

EBITDA

-154.60 MUSD

YoY

39.74%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Inventiva Sa is 2025 -154.60 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Inventiva Sa was 2024 -110.63 M USD. It decreases by 39.74% lower compared to the previous year.

The Inventiva Sa EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-37.72 M USD
Jan 1, 2019
-34.37 M USD
Jan 1, 2020
-33.70 M USD
Jan 1, 2021
-59.10 M USD
Jan 1, 2022
-64.76 M USD
Jan 1, 2023
-119.74 M USD
Jan 1, 2024
-110.63 M USD
Jan 1, 2025
-154.60 M USD
The Inventiva Sa EBITDA history
YEAREBITDAYoY
-154.60 MUSD+39.74%
-110.63 MUSD-7.60%
-119.74 MUSD+84.88%
-64.76 MUSD+9.59%
-59.10 MUSD+75.36%
-33.70 MUSD-1.96%
-34.37 MUSD-8.88%
-37.72 MUSD+59.05%
-23.72 MUSD+60.66%
-14.76 MUSD-16.06%
-17.59 MUSD+15.17%
-15.27 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Inventiva Sa Stock analysis

What does Inventiva Sa do? Inventiva Sa is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company focuses on developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases. Inventiva Sa is listed on the stock market with the ticker IVA and ISIN US46124U1079. It went public through an IPO on July 10, 2020. The company has 77 employees and operates within the Health Care sector. Its primary product development includes Lanifibranor, a peroxisome proliferator-activated receptor agonist currently in the NATiV3 Phase 3 clinical trial for treating adult patients with MASH. Additionally, the company is developing Odiparcil for mucopolysaccharidoses and has a pre-clinical program targeting TGF-ß for idiopathic pulmonary fibrosis. Inventiva Sa's website is https://inventivapharma.com. The company operates internationally, with its headquarters located in Daix, France. It is incorporated under French law, though the founding year is not specified in the provided information. The company's research and development efforts are centered on innovative therapeutic approaches for serious medical conditions. Inventiva Sa is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Inventiva Sa stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Inventiva Sa is -154.60 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Inventiva Sa changed from -110.63 M USD to -154.60 M USD, representing a 39.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Inventiva Sa since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Inventiva Sa historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Inventiva Sa

All Key Metrics — Inventiva Sa